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Background: Mutations affecting the Na+/ K+ ATPase (a.k.a. the sodium-potassium pump) genes cause conditional
locomotor phenotypes in flies and three distinct complex neurological diseases in humans. More than 50 mutations
have been identified affecting the human ATP1A2 and ATP1A3 genes that are known to cause rapid-onset Dystonia
Parkinsonism, familial hemiplegic migraine, alternating hemiplegia of childhood, and variants of familial hemiplegic
migraine with neurological complications including seizures and various mood disorders. In flies, mutations affecting
the ATPalpha gene have dramatic phenotypes including altered longevity, neural dysfunction, neurodegeneration,
myodegeneration, and striking locomotor impairment. Locomotor defects can manifest as conditional bang-sensitive
(BS) or temperature-sensitive (TS) paralysis: phenotypes well-suited for genetic screening.
Results: We performed a genome-wide deficiency screen using three distinct missense alleles of ATPalpha and
conditional locomotor function assays to identify novel modifier loci. A secondary screen confirmed allele-specificity of
the interactions and many of the interactions were mapped to single genes and subsequently validated. We successfully
identified 64 modifier loci and used classical mutations and RNAi to confirm 50 single gene interactions. The genes
identified include those with known function, several with unknown function or that were otherwise uncharacterized,
and many loci with no described association with locomotor or Na+/K+ ATPase function.
Conclusions: We used an unbiased genome-wide screen to find regions of the genome containing elements
important for genetic modulation of ATPalpha dysfunction. We have identified many critical regions and narrowed
several of these to single genes. These data demonstrate there are many loci capable of modifying ATPalpha
dysfunction, which may provide the basis for modifying migraine, locomotor and seizure dysfunction in animals.
Keywords: Drosophila melanogaster, ATPalpha, Sodium pump, Temperature-sensitive paralysis, Conditional
paralysis, Seizure, Migrane, Screen, Genome-wide, Seizure suppressorBackground
In many organisms, highly conserved Na+/K+ ATPases
are responsible for maintaining ion gradients across the
plasma membrane through ATP-dependent asymmetric
translocation of Na+ and K+ ions. These ion gradients
maintain the resting potential of cells, which facilitates
neural signaling and many essential secondary processes.
Mature Na+/K+ ATPase complexes are heteromultimers
of alpha, beta, and gamma subunits in mammals. Flies
express only the alpha and beta subunits, the former of
which is known as ATPalpha. Like its mammalian* Correspondence: mjp44@pitt.edu
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unless otherwise stated.homologue, ATPalpha contains ten transmembrane
domains and has the ATP-dependent catalytic activity
essential for pump function [1-3].
Mutations affecting the alpha subunit of the Na+/K+
ATPase in humans are associated with at least three hu-
man diseases: Rapid-onset Dystonia Parkinsonism (RDP),
Familial Hemiplegic Migraine (FHM), and Alternating
Hemiplegia of Childhood (AHC; [4]). RDP is a severe
DOPA non-responsive form of dystonia the etiology of
which is poorly understood [5]. FHM, possibly the most
severe form of migraine, is associated with a debilitating
partial paralysis, and currently is largely untreatable [6].
AHC is a severe childhood locomotor disease associated
with recurring acute bouts of paralysis and muscle weak-
ness, and general developmental delays (reviewed by [7]).
Recently Sasaki and colleagues have described severalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Primary screen summary
DTS1 CJ5 CJ10
Number tested in primary screen 386 393 358
% of Kit tested 83% 84% 77%
Avg. Response (Sec.) 34 88 42
St. Dev. (Sec.) 26.4 74.6 46.1
Normal Range (Sec.) 20-60 20-190 10-150
Number selected for verification 89 69 78
Screened phenotype TS BS BS
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AHC and RDP [8]. All of these diseases are complex
neuromuscular conditions associated with marked loco-
motor dysfunction and for which the underlying patho-
genesis is poorly understood.
Drosophila conditional mutants have been isolated
based upon temperature-sensitive (TS) or bang-sensitive
(BS) paralysis phenotypes over the past many decades. TS
mutants generally become paralyzed in less than five mi-
nutes at 38°C and BS mutants paralyze in response to
20 seconds of mechanical stress. These classes of mutants
have proven informative and have defined many essential
components of neural signaling [9-15]. Conditional TS
mutations typically affect critical neural proteins and in-
clude well-studied genes such as para (voltage-dependent
NaCH), NapTS (RNA helicase affecting para transcripts),
cacophony (a voltage-gated calcium channel), ATPalpha
(Na+/K+ ATPase), comatose (dNSF1), shibire (Dynamin),
syntaxin, synaptobrevin, and dao (regulator of Erg-type
K-channels), to name a few [15-24]. Conditional BS muta-
tions can also affect important neural signaling and ion
homeostasis proteins, such as para and ATPalpha [23,25].
They also affect many proteins with integral roles in bio-
energetics and mitochondrial function, such as sesB,
ATP6, kdn, eas, and SOD2 [26-30]. Interestingly, numer-
ous BS mutants have been shown to exhibit seizures and
model epilepsies (e.g. paraBSS1, ATP61, and Kazachoc;
[25,31,32]). BS and TS conditional mutants have proven
incredibly important to our understanding of neurobiol-
ogy and previous studies have successfully used them to
identify genes that modify these behaviors (e.g. [33-35]).
However, there are no reports of genome-wide screens for
modifier loci using these behavioral phenotypes in Dros-
ophila or studying ATPalpha in any model system. This
suggests that such an approach could yield novel loci in-
volved in regulating ion homeostasis or neural excitability.
It has previously been shown that mutations in ATPal-
pha result in profound neural and locomotor dysfunc-
tion in Drosophila [23,36-40]. Hypomorphic ATPalpha
alleles, such as ATPalpha2206, display BS paralysis and
phenocopy injection of the selective Na+/K+ ATPase in-
hibitor, ouabain [39]. The ATPalphaDTS1 mutation is a
dominant, conditional, gain-of-function, missense muta-
tion [23]. The mutation results in an E982K substitution
near the protein’s C-terminus (short isoform number-
ing). ATPalphaDTS1 heterozygotes exhibit rapid paralysis
at 38°C with complete penetrance. This is thought to be
a result of conditional neuronal hyperexcitability caused
by the mutation [23]. ATPalphaCJ5 and ATPalphaCJ10 are
also dominant missense mutations affecting evolution-
arily conserved amino acids [36]. However, they each
exhibit unique locomotor phenotypes. ATPalphaCJ5 be-
haves like a loss-of-function allele of ATPalpha, exhibiting
haploinsufficiency and BS paralysis [36]. ATPalphaCJ10exhibits BS and progressive TS phenotypes, suggesting
this is a loss-of-function allele that exhibits weak gain-of-
function features, which are uncovered with age [36].
Thus, ATPalphaDTS1, ATPalphaCJ5, and ATPalphaCJ10 are
all dominant, phenotypically well-characterized, and pos-
sibly functionally distinct, conditional locomotor mutants.
Such alleles are ideally suited for a modifier screen. Using
multiple alleles of ATPalpha increases the power of the
screen and affords the likelihood of identifying allele-
specific modifiers. Furthermore, to our knowledge, this is
the first report of a genome wide genetic screen in any
animal system using three distinct alleles of the same gene
in parallel to identify allele-specific interactions.
Deficiency screens have been effectively used for eluci-
dating novel gene interactions in Drosophila using various
phenotypes [41-43]. Deficiency (Df ) strains each have a
unique deletion of a segment of the genome. Phenotypic-
ally screening for genetic interactions between defined
point mutations and an individual defined deficiency is an
efficient way to identify modifier loci. Using a collection of
Dfs covering a high percentage of the genome (95-98%),
one can identify critical modifier loci anywhere in the gen-
ome. This provides an efficient yet powerful and unbiased
forward genetic approach. Critical loci can often be nar-
rowed to single genes using smaller deficiencies and single
gene disruptions. We have performed such a screen using
ATPalphaDTS1, ATPalphaCJ5 and ATPalphaCJ10, identified
64 critical modifier intervals, and successfully confirmed
50 single-gene modifiers, including numerous novel loci
of interest. These data suggest the existence of many
susceptibility loci capable of modifying migraine, loco-
motor and seizure dysfunction in animals and provide a
rich data set from which new targets for anti-migraine
or anti-epileptic drugs could be drawn.
Results
Primary genetic modifier screen
To identify new genes that interact with ATPalpha we per-
formed a deficiency screen using three characterized al-
leles: ATPalphaDTS1, ATPalphaCJ5 and ATPalphaCJ10. We
used the Bloomington Stock Center deficiency (Df) kit that
covers approximately 98% of the Drosophila genome. All
Figure 1 (See legend on next page.)
Talsma et al. Molecular Brain  (2014) 7:89 Page 3 of 16
(See figure on previous page.)
Figure 1 Distribution of phenotypic modifiers identified through a deficiency screen. A-C) ATPalpha mutant animals also bearing individual
unique chromosomal deficiencies (Df) were assayed for conditional locomotor function to identify modifiers. The data reveal a largely normal
distribution centered around a typical response (blue) for each mutant. Those deviating from the typical response were termed putative
enhancers (yellow) or suppressors (red). A) ATPalphaCJ5, Df double mutants and B) ATPalphaCJ10, Df double mutants were assayed for recovery
from mechanical stress at adult day 15. C) ATPalphaDTS1, Df double mutants were assayed for time to TS paralysis on adult day 1. A-C) The mean
response is shown as a dashed green line. +/− 0.5 Std. Dev. are indicated by gray shading.
Figure 2 Schematic of the deficiency screen workflow. Using the
Bloomington deficiency kit, 1137 initial interactions were screened
using ATPalphaCJ5, ATPalphaCJ10, or ATPalphaDTS1. Putative enhancers
and suppressors were selected for verification with a larger sample
size. Any verified interacting deficiencies were deemed critical
intervals. Once critical intervals were selected a screen for single
gene modifiers from within the intervals was performed using
available classical mutants and transgenic RNAi strains. If a modifier
was found it was retested with other ATPalpha alleles to determine
whether the interaction was allele-specific.
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one ATPalpha mutant allele and the vast majority of
strains were tested with multiple alleles (see Table 1). Each
of the three ATPalpha mutants was mated to each Df line.
F1 progeny bearing ATPalpha
DTS1 and each deficiency
were subjected to TS assays while progeny bearing ATPal-
phaCJ5 or ATPalphaCJ10 and each Df were assayed for BS.
The average response for ATPalphaDTS1, ATPalphaCJ5
and ATPalphaCJ10 Df double mutants was 34.8+/−25.3,
89.9+/−53.6 and 41.5+/−34.8 seconds, respectively
(Additional file 1). We used these values to identify pu-
tative genetic interactions. Df(3R)BSC819 contains a de-
letion of the ATPalpha locus and failed to complement
each mutant allele, as expected.
The data from the primary screen were organized graph-
ically by average time to recovery or paralysis for each
double mutant (Figure 1). In each case, the resulting data
formed a largely normal distribution. Double mutants that
deviated significantly from the mean were termed putative
enhancers or suppressors and were tested again in a verifi-
cation screen. The workflow for the genetic screen is
depicted in Figure 2. In the primary screen, 1137 interac-
tions were examined for the three conditional locomotor
mutants identifying 117 putative enhancer, suppressor, or
synthetic lethal regions. These interactions were examined
further in the verification screen.
Verification screen
To mitigate the effect of false positives and confirm that
interactions were reproducible before pursuing them
further, we performed a verification screen (an inde-
pendent experiment) with the putative modifiers. We
began the verification with 89 ATPalphaDTS1 modifiers
(Figure 1A), 69 ATPalphaCJ5 modifiers (Figure 1B), and
78 ATPalphaCJ10 modifiers (Figure 1C). After verifica-
tion, we took advantage of having two data sets (primary
and verification screen) and created a formula to deter-
mine the reproducibility of each putative genetic inter-
action (see Materials and Methods). We calculated a
reproducibility index (RI) and used it to help us identify
the most promising critical intervals. Dfs with the high-
est RIs were prioritized for mapping and secondary
screening. This approach yielded 7 putative ATPal-
phaDTS1 enhancers, 12 suppressors, and five synthetic
Table 2 Confirmed ATPalphaDTS1 interacting deficiencies
Df Name Enh/Sup Mean +/− SEM Total N RI Hits in region Coincidence
DTS1 Control 37.8 +/− 2.6 23 - - -
Df(3 L)Exel6092 Sup 76.4 +/− 33.4 11 6.27 spz5, FMRFaR, scramb2, aly CJ10
Df(2R)ED1725 Sup 209.8 +/− 57.0 6 4.87
Df(2R)BSC361 Sup 87.8 +/− 10.6 16 4.68 Stj CJ10
Df(3 L)BSC33 Sup 103.9 +/− 34.4 14 4.64
Df(3 L)Exel8104 Enh 27.3 +/− 27.3 11 3.18
Df(3R)BSC486 Enh 17.2 +/− 1.7 19 2.65 CJ10
Df(2 L)BSC180 Sup 85.3 +/− 16.5 25 2.13 Rbp9 CJ10
Df(3R)Exel6210 Sup 151.3 +/− 42.9 11 2.02
Df(2R)BSC383 Sup 129.1 +/− 40.9 11 1.80
Df(2 L)BSC278 Sup 52.3 +/− 14.9 25 1.54
Df(3 L)BSC23 Enh 11.2 +/− 1.1 14 1.53 spz5, scramb2, rasp, aly CJ5, CJ10
Df(2 L)Exel6005 Sup 73.9 +/− 23.1 19 1.51
Df(3R)BSC650 Enh 22.1 +/− 2.3 13 1.20
Df(2 L)ED1203 Enh 21.2 +/− 2.1 13 0.92 Ham CJ5
Df(3R)ED2 Enh 20.0 +/− 2.6 25 0.88
Df(2R)ED3728 Sup 46.3 +/− 8.2 15 0.86
Df(1)BSC767 Sup 138.2 +/− 26.7 13 0.82
Df(2R)M60E Sup 48.1 +/− 5.9 25 0.74 Rpl19, pain
Df(2 L)ED629 Enh 27.1 +/− 2.9 13 0.49 Glutactin, sema-1a
Df(3R)ED7665 Enh/Leth - - CJ10
Df(3R)ED6361 Enh/Leth - -
Df(3 L)BSC375 Enh/Leth - -
Df(3R)BSC467 Enh/Leth - - CJ10
Df(1)BSC708 Enh/Leth - -
Df(3R)BSC819 Enh/Leth - - ATPalpha All Enh/Leth
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The ATPalphaCJ5 screen yielded 13 enhancers, 10 sup-
pressors, and four synthetic lethal combinations
(Table 3). The ATPalphaCJ10 primary screen yielded 17
enhancers, 11 suppressors, and one synthetic lethal
(Table 4).
Single gene identification and testing
After the verification of critical intervals, genes contained
within these intervals were selected for testing. Where
practical large intervals were narrowed using smaller Dfs.
We obtained classical alleles for integral genes from
Bloomington, when possible. Each single gene mutant was
mated to the ATPalpha allele it putatively modified and to
w1118. All single gene mutants displayed no BS or TS
phenotype as heterozygotes (data not shown). Heterozy-
gous double mutants were again assayed for TS or BS with
age matched controls. Significant interacting single genemutants were also tested with the other ATPalpha alleles
(Figure 2). Twenty single gene interactions were found
using classical mutants for ATPalphaDTS1 including 19
single gene enhancers and one single gene suppressor.
Ten single gene suppressors were found for ATPalphaCJ5.
Twenty-four single gene interactions were found with
ATPalphaCJ10, all but one of which showed suppression of
the mutant phenotypes. In total, 35 single gene interac-
tions were found and, importantly, 14 different genes had
effects with more than one ATPalpha allele (Table 5).
Gal4 driven RNAi strains result in a loss-of-function
phenotype and are well-suited to confirm the hypo-
morphic effect of a heterozygous Df. RNAi knockdown
was driven with da-Gal4 in ATPalpha mutant back-
grounds. Daughterless transcripts are stably expressed
throughout the life of a fly and are detectable in every tis-
sue by the FlyAtlas affymetrix array analysis [72,73]. We
used this driver to ubiquitously express the RNAi
Table 3 Confirmed ATPalphaCJ5 interacting deficiencies
Df Name Enh/Sup Mean ± SEM Total N RI Hits in region Coincidence
CJ5 Control 100.0 +/− 11.4 28 - - -
Df(3 L)BSC797 Enh 240.6 +/− 17.3 14 4.03
Df(2 L)BSC214 Enh 178.7 +/− 22.6 15 2.38
Df(3 L)ED4475 Enh 172.4 +/− 21.4 16 1.97 CJ10
Df(2 L)BSC781 Sup 16.2 +/− 4.2 25 1.93 Cact, CG5888
Df(3R)BSC547 Enh 165.0 +/− 24.0 17 1.81 Sro, Dop1r2, ppk21
Df(3 L)M21 Enh 182.5 +/− 26.2 13 1.80
Df(2R)BSC199 Enh 168.8 +/− 24.2 14 1.63
Df(3R)ED5495 Enh 182.0 +/− 24.0 16 1.62
Df(2R)PK1 Sup 26.9 +/− 8.7 20 1.57 Pu
Df(2 L)Exel6005 Enh 235.9 +/− 22.6 13 1.55
Df(2 L)H20 Sup 29.2 +/− 6.4 25 1.52
Df(2 L)ED1203 Sup 31.0 +/− 4.8 23 1.52 ham, ddc DTS1
Df(3 L)BSC23 Sup 31.6 +/− 8.0 17 1.50 rasp, spz5, scramb2, aly DTS1, CJ10
Df(2 L)J39 Sup 23.0 +/− 4.7 21 1.43 FKBP59 CJ10
Df(2R)BSC267 Enh 144.7 +/− 24.7 3 1.38
Df(1)BSC825 Sup 36.7 +/− 7.2 9 1.37
Df(2 L)BSC213 Enh 146.3 +/− 46.2 8 1.35
Df(3 L)Exel6112 Enh 143.1 +/− 27.7 14 1.35 CJ10
Df(2 L)ED489 Sup 41.4 +/− 16.2 13 1.28 Ndae1 CJ10
Df(2 L)ED8142 Sup 38.9 +/− 7.9 24 1.20
Df(2R)BSC429 Sup 40.1 +/− 16.4 16 1.15
Df(2 L)BSC295 Enh 181.7 +/− 20.2 15 1.09
Df(2 L)BSC149 Enh 107.1 +/− 41.2 12 1.01
Df(2 L)BSC233 Enh/Leth - -
Df(3 L)BSC451 Enh/Leth - -
Df(3R)BSC469 Enh/Leth - - CJ10
Df(3R)BSC491 Enh/Leth - -
Df(3R)BSC819 Enh/Leth - - ATPalpha All Enh/Leth
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mediated knockdown of candidate genes was compared
to age matched controls lacking the UAS-RNAi con-
struct. Twenty-five different genes showed interactions
using this method, including 10 genes already identified
in the classical mutant screen. Fourteen interactions were
identified with ATPalphaDTS1, with nine enhancers and
five suppressors. Seventeen interactions, with two en-
hancers and 15 suppressors, were identified for ATPal-
phaCJ5. Thirteen interactions, all suppressors, were
confirmed with ATPalphaCJ10. In total 15 different genes
showed a genetic interaction with two or more ATPalpha
alleles (Table 6). In total we have identified 50 genes that
interact with ATPalpha, 25 of which were confirmed to
interact with at least two independent alleles.Discussion
The Na+/K+ATPase is central to maintaining cytosolic ion
homeostasis suggesting that many of the genes identified in
our screen would encode proteins that affect cytosolic ion
concentrations and, indeed, this was the case (Figure 3A).
Nearly 25% of the genes we identified encode proteins with
a known function in ion transport. In our search for single
gene modifiers we selected genes known to be expressed in
the nervous system. Unsurprisingly, ~50% of our hits are
known to cause some neuronal defect when knocked out
(Figure 3B). For example, most of the cell adhesion and
paracrine signaling molecules we found, such as Galectin
(Tables 5 and 6, Figure 4), Glt (Tables 5 and 6), and Sema-
1a (Table 5) were previously known to cause malformed or
improperly targeted synapses [45,48-50]. However, about
Table 4 Confirmed ATPalphaCJ10 interacting deficiencies
Df Name Enh/Sup Mean +/− SEM Total N RI Hits in region Coincidence
CJ10 Control 50.3 +/− 7.1 17 - - -
Df(3R)BSC486 Enh 168.5 +/− 38.8 6 4.92 DTS1
Df(3 L)Exel6112 Enh 144.6 +/− 15.4 18 4.20 CJ5
Df(2 L)BSC180 Enh 151.7 +/− 34.5 9 2.93 Rbp9 DTS1
Df(2 L)TW161 Enh 103.1 +/− 18.2 12 2.89
Df(3R)BSC469 Enh 96.5 +/− 22.9 11 2.59 CJ5
Df(3R)BSC681 Enh 98.7 +/− 49.4 6 2.32
Df(3R)A113 Enh 92.4 +/− 8.8 14 2.16
Df(3R)BSC501 Enh 91.8 +/− 7.8 14 2.10 CG14508
Df(3R)ED5495 Enh 139.6 +/− 34.5 7 1.98
Df(3 L)Exel6092 Enh 142.8 +/− 31.5 20 1.85 spz5, scramb2, FMRFaR, aly DTS1
Df(2R)BSC664 Enh 60.2 +/− 14.1 11 1.77
Df(3R)Exel6196 Enh 109.1 +/− 28.5 11 1.74
Df(3 L)BSC410 Enh 85.3 +/− 11.1 12 1.54
Df(3 L)ED4475 Sup 8.0 +/− 1.6 7 1.48 CJ5
Df(3 L)BSC23 Sup 8.0 +/− 3.0 18 1.43 rasp, spz5, scramb2, aly DTS1, CJ5
Df(2 L)BSC240 Enh 91.8 +/− 10.9 24 1.43 Nckx30C, ppk11, nAChR-alpha6, FKBP59
Df(2 L)J39 Sup 7.9 +/− 2.2 25 1.43 FKBP59 CJ5
Df(2R)BSC361 Enh 114.0 +/− 26.3 8 1.29 Stj DTS1
Df(2R)BSC661 Enh 78.0 +/− 10.9 23 1.25
Df(3R)ED5577 Sup 14.0 +/− 2.0 13 1.20
Df(2 L)ED489 Sup 12.1 +/− 2.6 25 1.19 Ndae1 CJ5
Df(3 L)ED230 Sup 13.7 +/− 3.7 10 1.17
Df(4)ED6380 Sup 12.6 +/− 3.6 25 1.14
Df(3 L)BSC113 Sup 14.3 +/− 1.7 15 1.13 aay
Df(2 L)ED793 Sup 16.2 +/− 4.1 25 1.09 Dyrk2, NimB5, nAChRα5
Df(2 L)BSC149 Sup 16.1 +/− 3.3 14 1.09
Df(3R)ED7665 Sup 16.5 +/− 5.1 21 1.06 DTS1
Df(3 L)BSC442 Enh 79.1 +/− 10.4 15 1.02
Df(3R)BSC467 Enh/Leth - - DTS1
Df(3R)BSC819 Enh/Leth - - ATPalpha All Enh/Leth
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function. Additionally, many genes we identified encode
proteins implicated in signaling pathways. In particular we
found proteins involved in developmental signaling path-
ways, such as Wingless and Hedgehog (rasp (Tables 5 and 6)
and slmb (Table 5)), and neuronal growth and survival path-
ways (spz5 (Tables 5 and 6)).
Spz5 (Figure 5) is especially interesting because it has
recently been identified as a Drosophila neurotrophin that
signals through a Toll receptor [61,62]. Both Slmb and
Cact (Table 5) were also identified by our screen and both
may function downstream of Spz5. In mammals and flies,
Toll signaling activates NF-κB transcription factors, typic-
ally through the degradation of an inhibitor of NF-κB(I-κB), such as Cact. Phosphorylated I-κB is targeted for
degradation, allowing NF-κB-like transcription factors to
translocate to the nucleus. Slmb and its mammalian
homolog β-TrCP regulate phospho-I-κB. β-TrCP, and
likely Slmb, target an E3 ubiquitin ligase complex to
phospho-I-κB and mediate its degradation via ubiquitin
proteasome system [68]. Interestingly, we have also iden-
tified Uch-L5 (Table 6) in our screen, a member of the
26S regulatory complex which is likely responsible for
the deubiquitylation of proteins as they enter the 26S
proteasome [81].
Previously published studies of Slmb, and Spz5 show
that they play an important role in neural development.
Slmb is involved in pruning dendrites and axons during
Table 5 Single gene effects confirmed for ATPalpha alleles using classical mutants
Cytological
region
Gene Genotype Putative
function#
ATPα Allele Nature of
interaction
Significance
10B3 l(1)10Bb E04588 Spliceosome component [44] CJ10 Suppressor *
21B1-21B1 Galectin DG25505 Cell surface protein, galactoside binding [45] DTS1 Enhancer ***
23C9-23C9 Rbp9 Δ1 RNA binding [46] DTS1 Enhancer *
23C9-23C9 Rbp9 Δ1 " CJ5 Suppressor ****
27E-28B1 Ndae1 MB05294 Sodium driven anion exchanger [47] CJ5 Suppressor *
27E-28B1 Ndae1 MB05294 " DTS1 Enhancer *
27E-28B1 Ndae1 MB05294 " CJ10 Suppressor *
29B4-29E4 Sema-1a K13702 Axon guidance signal and receptor [48,49] DTS1 Enhancer *
29B4-29E4 Glt EY22126 Cell surface glycoprotein [50] DTS1 Enhancer ****
29B4-29E4 Glt EY22126 “ CJ10 Suppressor *
30C7-30 F2 Nckx30C E00401 Sodium/Calcium/Potassium exchanger [51] CJ10 Enhancer *
30C7-30 F2 Ppk11 MB02012 Excitatory sodium channel [52] CJ10 Suppressor ***
30C7-30 F2 Ppk11 MB02012 “ DTS1 Suppressor ****
30C7-30 F2 Ppk11 MB02012 “ CJ5 Suppressor ****
30C7-30 F2 nAChRα6 MB06675 ACh receptor subunit CJ10 Suppressor *
30C7-30 F2 nAChRα6 MB06675 “ CJ5 Suppressor ****
31C-32E FKBP59 EY03538 Calcium channel regulator [53] DTS1 Enhancer *
31C-32E FKBP59 EY03538 " CJ5 Suppressor ***
31C-32E FKBP59 EY03538 “ CJ10 Suppressor ***
33A8-33B1 Pde1c C04487 cAMP/cGMP phosphodiesterase [54] CJ5 Suppressor ****
34E4-35B4 Dyrk2 1 Serine/Threonine kinase [55] DTS1 Enhancer ***
34E4-35B4 Dyrk2 1 " CJ10 Suppressor ****
34E4-35B4 Nimb5 MI01793 Bacterial defense CJ10 Suppressor **
34E4-35B4 nAChRα5 MB11647 ACh Receptor subunit CJ10 Suppressor *
35 F1-36A1 Cact 7 Inhibitor of NF-κB [56] CJ10 Suppressor ****
36A8-36 F1 Beat-Ia & Fas3 3/E25 Neuronal immunoglobulin-like proteins CJ5 Suppressor *
25 F1-36A1 CG5888 MB00188 Toll 3 like receptor DTS1 Enhancer ****
25 F1-36A1 CG5888 MB00188 " CJ5 Suppressor ****
46 F1-47A9 CG42732 MB04544 Predicted potassium channel DTS1 Enhancer ****
46 F1-47A9 Rpl41/NaCP60E EP348 Ribosomal protein; voltage-gated Na+ channel [57] CJ10 Suppressor *
46 F1-47A9 CG42732 MB04544 Predicted potassium channel CJ5 Suppressor **
46 F1-47A9 Gαo MI00833 Heterotrimeric G-protein subunit CJ10 Suppressor ****
46 F1-47A9 CYP49A1 & Gαo MB04922 Cytochrome P450 & heterotrimeric G-protein subunit DTS1 Enhancer ****
50B1 CG33156 MB05931 Predicted NAD+ kinase DTS1 Enhancer ****
57C5-57 F6 Pu r1 GTP cyclohydrolase [58] CJ5 Suppressor **
57C5-57 F6 Pu r1 “ CJ10 Suppressor ****
60E6-60E11 Pain EP2451 TRP calcium channel [59] DTS1 Enhancer **
60E6-60E11 Pain EP2451 “ CJ10 Suppressor ****
60E6-60E11 Rpl19 K03704 Ribosomal component [60] DTS1 Enhancer ****
62E8-63B6 Spz5 E03444 Neurotrophin [61,62] DTS1 Enhancer **
62E8-63B6 Spz5 E03444 “ CJ10 Suppressor ****
62E8-63B6 Aly 1 Regulator of transcription [63,64] DTS1 Enhancer ****
62E8-63B6 Rasp m47 Palmitoyl transferase [65,66] DTS1 Enhancer **
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Table 5 Single gene effects confirmed for ATPalpha alleles using classical mutants (Continued)
62E8-63B6 Rasp m47 “ CJ10 Suppressor ****
63A3-63A3 Scramb2 EY01180 Predicted phosphatidyl serine scramblase DTS1 Enhancer ****
63A3-63A3 Scramb2 EY01180 " CJ10 Suppressor ****
67A2-67D13 Aay S042314 Predicted Phosphoserine phosphatase CJ10 Suppressor **
93B9-93D4 Slmb 295 Ubiquitin ligase [67,68] DTS1 Enhancer **
93B9-93D4 Slmb 295 “ CJ10 Suppressor ****
93B9-93D4 Sec15 2 Protein trafficking [69,70] DTS1 Enhancer **
93B9-93D4 Sec15 2 “ CJ10 Suppressor ****
93B9-93D4 RhoGAP93B EY07136 Rac1 GAP [71] DTS1 Enhancer *
98 F10-99B9 CG14508 G9163 Predicted cytochrome C DTS1 Enhancer ***
98 F10-99B9 CG14508 G9163 Predicted cytochrome C CJ10 Suppressor ****
99E1-3Rt Sro 1 Ecdysone biosynthetic pathway CJ10 Suppressor *
Many genes had an interaction with more than one allele, although some appear to be allele specific. Double mutants were compared to ATPalpha*/+ and
heterozygous classical mutant controls. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
#Function per flybase.org and / or listed citation.
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guidance cue in the embryonic nervous system [61]. Inter-
estingly, animals heterozygous for a loss of function allele
of either gene displayed no phenotype in neurons [61,85].
In contrast, our screen examined heterozygous double
mutants and found large effects, suggesting ATPalpha
mutants are sensitive to otherwise inconsequential
changes in neuronal development or another unappre-
ciated function of these proteins. Furthermore, a
seemingly insignificant disruption of neuronal survival
signals early in development may have dramatic
phenotypic effects for ATPalpha mutants since hetero-
zygosity of Slmb, or Spz5 suppressed the loss-of-
function ATPalpha phenotype. Additionally, numerous
developmental genes were identified implying that
neurodevelopmental changes may profoundly affect Na+/K+
ATPase function or this is a general and potent mechanism
to modulate locomotor function.
Another interesting possibility is that loss-of-function
ATPalpha mutations are disrupting neuronal development
through alterations in NF-κB signaling. It has been shown
that sub-inhibitory concentrations of ouabain activate NF-
κB via an Na+/K+ ATPase dependent mechanism in rat
kidney cells. The effect is mediated by slow, inositol
triphosphate-dependent, calcium oscillations likely caused
by shifting electrochemical gradients [86]. More recently,
agrin, a protein involved in synapse formation at NMJs
and in the CNS, has been shown to bind to and inhibit
the mammalian Na+/K+ ATPase α3 isoform. Furthermore,
agrin seems to bind at the same site as ouabain because a
protein fragment can prevent ouabain inhibition of the
Na+/K+ ATPase [87]. Thus it is possible that agrin exerts
its effects through NF-κB. If a similar pathway exists in
flies it would likely be constitutively active in our loss-of-
function mutants and its dysregulation could causedevelopmental changes, which might increase seizure sus-
ceptibility. This is consistent with our finding that knock-
down of proteins required for NF-κB activation suppresses
seizures in our loss-of-function mutants. NF-κB activation
may be caused by calcium oscillations [86], making it pos-
sible that some of the calcium channels we found also play
a role in this pathway. FKBP59 (Figure 6) is particularly in-
teresting because it inhibits an inositol triphosphate sensi-
tive, non-specific calcium channel, TrpL [53]. Inhibition of
calcium channels would likely be required in calcium oscil-
lations. The preponderance of hits related to the NF-κB
pathway suggests a possible role for this pathway in seizure
pathogenesis.
In most cases the ATPalphaCJ5 and ATPalphaCJ10 mutant
phenotypes were modified in the same direction (enhance-
ment or suppression) and they never had opposite phe-
notypes in our screen. This is consistent with the
finding that both exhibit loss-of-function characteris-
tics. The ATPalphaDTS1 phenotype, however, usually
contrasted with the phenotypes of ATPalphaCJ5 and
ATPalphaCJ10. This is intriguing as ATPalphaDTS1 is a
gain-of-function mutation that can be reverted by a
second site mutation to give the characteristic ATPal-
pha loss-of-function phenotype [23]. In accord with
this fact the vast majority (~ 80%) of the single gene
interactions with ATPalphaDTS1 modified the loss-of-
function alleles in the opposite direction or not at all.
Reduction of Ppk11, Ppk21, and Ppk24 function all
suppressed the phenotypes of ATPalphaDTS1 and an-
other allele. All three are predicted epithelial sodium
channels (DEG/eNaCs) that function in nociception,
mechanosensation, gustation and other sensory functions
(Reviewed in [88] and [89]). Thus, it is possible that
altered sensory function may underlie the ATPalphaDTS1
paralysis phenotype and that a reduction in the ability of
Table 6 Single gene effects confirmed for ATPalpha alleles using RNAi
Cytological region Gene Putative function# ATPα Allele Nature of interaction Significance
21A1-21B1 Galectin Galactoside binding [45] CJ10 Suppressor **
21A1-21B1 Galectin “ CJ5 Suppressor ***
22 F4-22 F4 CG3528 Unknown DTS1 Enhancer *
22 F4-22 F4 CG3528 CJ10 Suppressor *
22 F4-22 F4 CG3528 CJ5 Suppressor *
27E-28B1 Ndae1 Na + driven anion exchanger [47] CJ5 Enhancer *
29B4-29E4 Glt Cell surface glycoprotein [50] CJ10 Suppressor *
30C8-30C9 Ppk11 Sodium channel [52] CJ5 Suppressor **
31C-32E FKBP59 Calcium channel regulator [53] CJ5 Suppressor ***
31C-32E FKBP59 “ DTS1 Enhancer *
33A1-33A1 Vha100-5 ATPase, proton transport DTS1 Enhancer *
33A2-33A2 Esc Histone methyltransferase component [74] DTS1 Enhancer ***
33A2-33A2 Esc “ CJ10 Suppressor **
34E4-35B4 Dyrk2 Serine/Threonine kinase [55] DTS1 Enhancer *
34E4-35B4 Dyrk2 “ CJ5 Suppressor ***
37A2-37A4 Ham Transcription factor [75] DTS1 Suppressor *
37A2-37A4 Ham “ CJ5 Suppressor **
37C1-37C1 Ddc Amino acid decarboxylase [76] CJ5 Suppressor ***
25 F1-36A1 CG5888 Toll 3 like Receptor CJ10 Suppressor **
25 F1-36A1 CG5888 “ CJ5 Suppressor *
50C5-50C6 Stj Voltage-gated calcium channel regulatory subunit [77,78] DTS1 Enhancer ****
50C5-50C6 Stj “ CJ5 Enhancer **
51D1-51D1 Cyp6a19 Cytochrome P450 CJ10 Suppressor *
62E8-63B6 Spz5 Neurotrophin [61,62] DTS1 Suppressor **
62E8-63B6 Spz5 “ CJ10 Suppressor *
62E8-63B6 Rasp Palmitoyl transferase [65,66] CJ5 Suppressor ***
63A3-63A3 FMRFaR Neuropeptide receptor [79] DTS1 Enhancer **
63A3-63A3 FMRFaR “ CJ10 Suppressor **
63A3-63A3 FMRFaR “ CJ5 Suppressor ****
64C2-64C5 Con Homophilic cell adhesion [80] DTS1 Suppressor *
64C2-64C5 Con “ CJ5 Suppressor **
67A2-67D13 Aay Predicted phosphoserine phosphatase CJ10 Suppressor *
67A2-67D13 Aay “ CJ5 Suppressor **
67B9-67B9 Uch-L5 26S Proteasome component [81] DTS1 Enhancer *
67D11-67D11 Scramb1 Phosphatidyl serine scramblase CJ10 Suppressor **
99B5-99B6 Dop1R2 Dopamine 1-like receptor [82,83] CJ5 Suppressor ***
99B6-99B6 Ppk21 Sodium channel DTS1 Suppressor **
99B6-99B6 Ppk21 “ CJ10 Suppressor *
100B9-100B9 Ppk24 Sodium channel DTS1 Suppressor **
100B9-100B9 Ppk24 “ CJ5 Suppressor *
100B9-100B9 Ppk24 “ CJ10 Suppressor **
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Table 6 Single gene effects confirmed for ATPalpha alleles using RNAi (Continued)
100C1-100C1 CG11340 Predicted chloride channel DTS1 Suppressor *
100C1-100C1 CG11340 “ CJ5 Suppressor ***
100C1-100C1 CG11340 “ CJ10 Suppressor *
Many genes had an interaction with more than one allele, although some appear to be allele specific. RNAi knockdowns were compared with ATPalpha*, daGal4/+ controls.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
#Function per flybase.org and/or listed citation.
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perature is sufficient to suppress the TS paralysis. This
possibility is consistent with the kinetics of recovery after
animals are returned to the permissive temperature. This
is also intriguing as the locomotor dysfunction resulting in
hemiparalysis in FHM patients has been reported to be
associated with sensory dysfunction and FHM patients
report having prolonged visual auras [90-92].
Conclusions
FHM, RDP, and AHC are complex human neurological
diseases associated with mutations affecting the catalytic
alpha subunit of the Na+/K+ ATPase [4-6]. Currently,Figure 3 Distribution of validated genetic modifiers. A. Protein
function of modifiers, as annotated on flybase.org, grouped into
major categories. Stj, rasp, slmb, Rpl41/NaCP60E, and punch were
included in two categories. B. Modifier loci categorized according to
mutant phenotypes (when available). FKBP59, Cact, Scramb1, and Stj
were associated with two phenotypic categories.there is no cure or effective treatment for these diseases.
Using three Drosophila strains with different missense
mutations in ATPalpha we have performed a large-scale
deficiency screen to identify novel genes that interact with
the gene encoding the Na+/K+ATPase alpha subunit. In
total, we have identified 50 genes that interact with ATPal-
pha, 25 of which were demonstrated to interact with at
least two independent alleles. We have also implicated
50 critical intervals/deficiency regions for which we
have yet to identify individual genes that interact with
ATPalpha (Tables 2, 3 and 4). Modifier loci that encode
proteins expressed in the adult, especially those that
phenotypically suppress ATPalpha dysfunction, provide
proteins/pathways that could be viable targets for the
development of new migraine or anti-epileptic drugs.
Additionally, studies of these loci and how they modify
ATPalpha dysfunction will help us understand epilepsy,
hemiplegia and migraine disease pathogenesis in animals.
Materials and methods
Drosophila strains
Flies were maintained on standard cornmeal-molasses agar
medium at 21-22°C. Chromosomal deficiencies were ob-
tained from the Bloomington Deficiency Kit from the
Bloomington Stock Center (order date January 2010). The
Df Kit we received contained 467 stocks with deletions span-
ning 97.8% of the Drosophila genome. Three Na+/K+
ATPase alpha subunit mutants were used: ATPalphaDTS1
[23], ATPalphaCJ5 and ATPalphaCJ10 [36]. The other Dros-
ophila strains used were obtained from the Vienna Dros-
ophila RNAi Center (VDRC) or Bloomington Stock Center.
Locomotor assays
F1 offspring heterozygous for an ATPalpha allele and
each individual Df were collected upon eclosion (day 0)
and aged at 25°C on cornmeal-molasses medium.
Temperature sensitivity (TS) was assayed on day 1 and
bang sensitivity (BS) was assayed on day 15 as described
previously [23]. Aged flies were moved to an empty vial
in groups of 5 or fewer using an aspirator. For TS, the
vial was submerged in a water bath at 38°C such that the
flies were restricted to space in the vial below the water-
line. A timer was started when the vial was submerged
and time to paralysis was recorded for each fly. For BS,
the vial was mechanically shaken using a standard lab
Figure 4 Genetic interaction between Galectin and ATPalpha. Galectin; ATPalpha double mutants and ATPalpha*, Galectin RNAi flies for each
ATPalpha mutant were assayed and compared to ATPalpha* heterozygous controls. The RNAi knockdown was driven ubiquitously with
daughterless-Gal4 (daGAL4). The genotypes in each graph are: ATPalpha*/+ (green), GalectinDG25505/+;ATPalpha*/+ (red), daGal4,ATPalpha*/+ (blue),
and Galectin-RNAi/+;daGal4,ATPalpha*/+ (orange). Galectin mutants significantly enhanced the ATPalphaDTS1 phenotype while galectin-RNAi
significantly suppress ATPalphaCJ5 and ATPalphaCJ10 phenotypes. *p < 0.05, **p < 0.01, ***p < 0.001.
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20 seconds. Time to recovery for each fly was recorded.
Both conditional locomotor assays were stopped after
300 seconds.
Df Interaction screen
Initial Screens
Males with autosomal deficiencies were mated to ATPal-
phaDTS1, ATPalphaCJ5, and ATPalphaCJ10 virgin females,
and X-linked deficiency virgin females were mated with
ATPalphaDTS1, ATPalphaCJ5, and ATPalphaCJ10 males. F1
progeny representing a total of 386 deficiency interactions
were tested with ATPalphaDTS1 animals (83% of Df kit),
393 were tested with ATPalphaCJ5 (84% of Df kit), and 358
were tested with ATPalphaCJ10 animals (77% of Df kit).Figure 5 Genetic interaction between Spz5 and ATPalpha. ATPalpha/Sp
mutant were assayed and compared to ATPalpha* heterozygous controls. T
graph are: ATPalpha*/+ (green), Spz5E03444/ATPalpha* (red), daGal4,ATPalpha
significantly enhanced the ATPalphaDTS1 phenotype but Spz5 RNAI signi
phenotype is suppressed in both the Spz5 mutant and RNAi. The ATPalp
*p < 0.05, **p < 0.01, ***p < 0.001.Each of the 467 Dfs we received was tested with at least
one ATPalpha allele, the vast majority were tested with
multiple alleles and >55% were tested with all three alleles.
Assays were performed as described above.Verification screen
Putative modifier Df strains identified in the initial
screen were retested in an independent experiment to
verify the findings and reduce the rate of false posi-
tives. In selecting Df stains to test again, we favored
Dfs that suppressed ATPalpha mutant phenotypes
and/or interacted with more than one ATPalpha allele.
During the verification screen all three ATPalpha
alleles were investigated.z5 double mutants and ATPalpha*, Spz5 RNAi flies for each ATPalpha
he RNAi knockdown was driven with da-Gal4. The genotypes in each
*/+ (blue), and Spz5-RNAi/daGal4,ATPalpha* (orange). Spz5 mutants
ficantly suppresses the ATPalpha DTS1 phenotype. The ATPalphaCJ10
haCJ5 phenotype was not significantly affected by loss of Spz5.
Figure 6 Genetic interactions between FKBP59 and ATPalpha. FKBP59; ATPalpha double mutants and ATPalpha*, FKBP59 RNAi flies were
assayed and compared to ATPalpha* heterozygous controls. The RNAi knockdown was driven with da-Gal4. The genotypes in each graph are:
ATPalpha*/+ (green), FKBP59E03444/+; ATPalpha*/+ (red), daGal4,ATPalpha*/+ (blue), and FKBP59-RNAi/+;daGal4,ATPalpha*/+ (orange). FKBP59
mutants significantly enhanced the ATPalphaDTS1 phenotype. The ATPalphaCJ5 phenotype is suppressed by both the FKBP59 mutant and RNAi.
*p < 0.05, **p < 0.01, ***p < 0.001.
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We developed an analysis called the Reproducibility
Index (RI) in order to guide our search for single gene
modifiers of the ATPalpha alleles. The goal of this
index was to rank the most promising Df intervals
based on the magnitude and reproducibility with which
they modified an ATPalpha allele phenotype. To this
end, we first calculated the number of standard devia-
tions of the Df, ATPalpha* double mutant mean from
the total mean of the primary screen of each ATPalpha
mutant using:
Num:Std:Dev: SDð Þ ¼ Meantotal−MeanDf
StdDevtotal
where StdDevtotal is the standard deviation of all defi-
ciencies in the primary screen, Meantotal is the mean
of all deficiencies in the primary screen, and MeanDf is
the mean response of a Df/ATPalpha double mutant.
Num.Std.Dev (#SD) was calculated for the mean re-
sponse of a Df double mutant in the primary (#SDprim)
and verification (#SDveri) screen. We reasoned that
these values provide a normalized metric of how much
a Df modified an ATPalpha phenotype in each trial.
We used these values to calculate the RI:
RI ¼ #SDprim þ#SDveri



−AV=2
where
Absolute Varience AVð Þ¼ #SDprim−#SDveri




The RI increases for Dfs that were further from the
total mean and decreases for Dfs that varied more across
the two trials. Thus, a high RI suggests that a region is
more likely to contain a gene that interacts with and
modifies an ATPalpha allele in a reproducible manner.In some intervals we were able to use small Dfs to nar-
row the interval further. We, again, prioritized strongly
suppressing intervals over enhancing intervals and inter-
vals that interacted with multiple alleles. Single genes
were selected from critical intervals using the G-Browse
feature (an annotated genome) of flybase.org. In some
very small intervals all genes in the region were tested.
In large intervals we necessarily focused on genes with
described expression within the nervous and or muscu-
lar systems, introducing a noted bias. Many of the alleles
chosen were P-element or classical mutations reported
to knockout the genes of interest. The stocks of interest
were ordered from the Bloomington Stock Center.
RNAi analysis
When classical mutants were unavailable for certain loci
or to confirm an interaction found using a classical mu-
tant, RNAi analysis was used to examine the gene in
question. RNAi stocks were ordered from the VDRC.
The RNAi transgenes were driven using daughterless
Gal4 strains (daGal4) in each ATPalpha mutant back-
ground. RNAi male flies were mated to ATPalpha,
daGal4 virgin females. Progeny were raised at 25°C, and
TS and BS tests were performed as described previously.
Data collection and statistics
Data were collected and organized using Microsoft Excel
(Redmond, WA). Data were analyzed in GraphPad Prism
5 (San Diego, CA). We used ANOVA to compare the
ATPalpha mutant heterozygotes, the classical mutant
heterozygotes, and flies heterozygous for both alleles.
Tukey’s multiple comparison test was performed to de-
termine if the double mutants were significantly differ-
ent from the ATPalpha mutant heterozygote and the
classical mutant heterozygote. Adjusted p-values are
Talsma et al. Molecular Brain  (2014) 7:89 Page 14 of 16reported in Table 5. The effect of RNAi transgenes was
analyzed using a Student’s t-test to determine if single
gene knockdowns significantly modified the phenotype
of ATPalpha*, daGal4 controls. Significant interactions
are reported in Table 6.
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